表紙:核酸検査の世界市場 (2021-2026年):産業動向・市場シェア・市場規模・成長予測・成長機会
市場調査レポート
商品コード
1037012

核酸検査の世界市場 (2021-2026年):産業動向・市場シェア・市場規模・成長予測・成長機会

Nucleic Acid Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版日: | 発行: IMARC Services Private Limited | ページ情報: 英文 146 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=128.85円
核酸検査の世界市場 (2021-2026年):産業動向・市場シェア・市場規模・成長予測・成長機会
出版日: 2021年11月10日
発行: IMARC Services Private Limited
ページ情報: 英文 146 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の核酸検査の市場規模は2015年から2020年にかけて力強い成長を示し、予測期間中は約8%のCAGRで成長すると予測されています。

細菌やウイルスによる感染症が世界的に増加しており、市場成長の重要な要因の一つとなっています。さらに、高度な診断システムへの需要が高まっていることも、市場の成長を後押ししています。また、広範なR&D活動や医療インフラの整備など、その他の要因も市場をさらに押し上げる要因となることが予測されています。

当レポートでは、世界の核酸検査の市場を調査し、市場概要、市場規模の推移・予測、製品タイプ・技術・エンドユーザー・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 序文

第2章 調査範囲・調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界の核酸検査市場

  • 市場概要
  • 市場パフォーマンス
  • COVID-19の影響

第6章 市場の内訳:製品タイプ別

  • 機器
  • 試薬・消耗品

第7章 市場の内訳:技術別

  • TMA
  • PCR
  • LCR
  • SDA
  • その他

第8章 市場の内訳:エンドユーザー別

  • 病院・診療所
  • 病理ラボ
  • 研究機関
  • その他

第9章 市場の内訳:地域別

  • 北米
  • アジア太平洋
  • 欧州
  • ラテンアメリカ
  • 中東・アフリカ

第10章 SWOT分析

第11章 バリューチェーン分析

第12章 ポーターズファイブフォース分析

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Agilent Technologies
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories Inc.
    • Danaher Corporation
    • F. Hoffmann-La Roche Ltd.
    • Illumina Inc.
    • Merck KGaA
    • Siemens Healthcare
    • Tecan Group AG
    • Thermo Fisher Scientific Inc.
目次
Product Code: SR1020G30_Report

The global nucleic acid testing market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 8% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Nucleic acid testing (NAT) refers to a molecular technique for screening viruses, bacteria or pathogenic nucleic acid in the blood, tissue or urine of the patient. It is conducted for forensic testing and to diagnose transfusion-transmitted infections, genetic diseases and cancer. It involves sample pooling through nucleic acid (NA) extraction, target NA amplification and target amplicon NA detection. The testing involves kits and consumables for performing polymerase chain reaction (PCR), strand displacement amplification (SDA), ligase chain reaction (LCR), transcription-mediated amplification (TMA) and NA sequence-based amplification (NASBA) processes. NAT is also used for the identification of diseases with no visible symptoms and resolving false reactive interpretations.

The increasing prevalence of infectious bacterial and viral diseases across the globe represents one of the key factors driving the growth of the market. Furthermore, the increasing demand for advanced diagnostic systems is also driving the market growth. In line with this, the onset of the coronavirus disease (COVID-19) has also enhanced the demand for NAT solutions to detect the antigens. NAT is widely used for the effective management of communicable diseases and accurate identification of the infecting agent. Additionally, various technological advancements, such as the development of novel biological diagnostic techniques, including signal and probe amplification systems, are acting as other growth-inducing factors. These innovative techniques aid in the early detection of the disease and minimizing the infectious period of the virus. Other factors, including extensive research and development (R&D) activities, along with improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global nucleic acid testing market, along with forecasts at the global, regional and country-level from 2021-2026. Our report has categorized the market based on region, product type, technology and end user.

Breakup by Product Type:

  • Instruments
  • Reagents and Consumables

Breakup by Technology:

  • TMA- Transcription-mediated Amplification
  • PCR- Polymerase Chain Reaction
  • LCR- Ligase Chain Reaction
  • SDA- Strand Displacement Amplification
  • Others

Breakup by End User:

  • Hospitals and Clinics
  • Pathology Laboratories
  • Research Institutes
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Agilent Technologies, Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Illumina Inc., Merck KGaA, Siemens Healthcare, Tecan Group AG and Thermo Fisher Scientific Inc. Key Questions Answered in This Report:

  • How has the global nucleic acid testing market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global nucleic acid testing market?
  • What are the key regional markets?
  • What is the breakup of the market based on the product type?
  • What is the breakup of the market based on the technology?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global nucleic acid testing market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Nucleic Acid Testing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Instruments
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Reagents and Consumables
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 TMA- Transcription-mediated Amplification
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 PCR- Polymerase Chain Reaction
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 LCR- Ligase Chain Reaction
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 SDA- Strand Displacement Amplification
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Pathology Laboratories
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Research Institutes
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Agilent Technologies
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Becton, Dickinson and Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bio-Rad Laboratories Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Danaher Corporation
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 F. Hoffmann-La Roche Ltd.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 SWOT Analysis
    • 14.3.7 Illumina Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Merck KGaA
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Siemens Healthcare
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Tecan Group AG
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Thermo Fisher Scientific Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis